Logo image of RIGL

RIGEL PHARMACEUTICALS INC (RIGL) Stock Fundamental Analysis

NASDAQ:RIGL - Nasdaq - US7665597024 - Common Stock - Currency: USD

18.71  -0.02 (-0.11%)

After market: 18.82 +0.11 (+0.59%)

Fundamental Rating

6

Overall RIGL gets a fundamental rating of 6 out of 10. We evaluated RIGL against 555 industry peers in the Biotechnology industry. Both the profitability and the financial health of RIGL get a neutral evaluation. Nothing too spectacular is happening here. RIGL is evaluated to be cheap and growing strongly. This does not happen too often! With these ratings, RIGL could be worth investigating further for value and growth investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

RIGL had positive earnings in the past year.
RIGL had a positive operating cash flow in the past year.
RIGL had negative earnings in 4 of the past 5 years.
In multiple years RIGL reported negative operating cash flow during the last 5 years.
RIGL Yearly Net Income VS EBIT VS OCF VS FCFRIGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

The Return On Assets of RIGL (21.13%) is better than 97.66% of its industry peers.
The Return On Equity of RIGL (200.24%) is better than 99.64% of its industry peers.
RIGL has a better Return On Invested Capital (31.74%) than 99.10% of its industry peers.
Industry RankSector Rank
ROA 21.13%
ROE 200.24%
ROIC 31.74%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RIGL Yearly ROA, ROE, ROICRIGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

RIGL's Profit Margin of 18.31% is amongst the best of the industry. RIGL outperforms 95.32% of its industry peers.
Looking at the Operating Margin, with a value of 21.63%, RIGL belongs to the top of the industry, outperforming 95.86% of the companies in the same industry.
With an excellent Gross Margin value of 89.64%, RIGL belongs to the best of the industry, outperforming 91.89% of the companies in the same industry.
RIGL's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 21.63%
PM (TTM) 18.31%
GM 89.64%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
RIGL Yearly Profit, Operating, Gross MarginsRIGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so RIGL is creating value.
The number of shares outstanding for RIGL has been increased compared to 1 year ago.
The number of shares outstanding for RIGL has been reduced compared to 5 years ago.
Compared to 1 year ago, RIGL has an improved debt to assets ratio.
RIGL Yearly Shares OutstandingRIGL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
RIGL Yearly Total Debt VS Total AssetsRIGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

RIGL has an Altman-Z score of -7.17. This is a bad value and indicates that RIGL is not financially healthy and even has some risk of bankruptcy.
RIGL has a Altman-Z score of -7.17. This is in the lower half of the industry: RIGL underperforms 67.93% of its industry peers.
RIGL has a debt to FCF ratio of 1.69. This is a very positive value and a sign of high solvency as it would only need 1.69 years to pay back of all of its debts.
RIGL has a better Debt to FCF ratio (1.69) than 94.59% of its industry peers.
RIGL has a Debt/Equity ratio of 2.42. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.42, RIGL is not doing good in the industry: 81.26% of the companies in the same industry are doing better.
Although RIGL does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
Industry RankSector Rank
Debt/Equity 2.42
Debt/FCF 1.69
Altman-Z -7.17
ROIC/WACC3.53
WACC8.99%
RIGL Yearly LT Debt VS Equity VS FCFRIGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RIGL has a Current Ratio of 2.20. This indicates that RIGL is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.20, RIGL is not doing good in the industry: 73.51% of the companies in the same industry are doing better.
A Quick Ratio of 2.13 indicates that RIGL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.13, RIGL is doing worse than 72.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.2
Quick Ratio 2.13
RIGL Yearly Current Assets VS Current LiabilitesRIGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

7

3. Growth

3.1 Past

RIGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 272.50%, which is quite impressive.
Looking at the last year, RIGL shows a very strong growth in Revenue. The Revenue has grown by 68.74%.
RIGL shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.77% yearly.
EPS 1Y (TTM)272.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226%
Revenue 1Y (TTM)68.74%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%80.58%

3.2 Future

RIGL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.94% yearly.
The Revenue is expected to grow by 12.13% on average over the next years. This is quite good.
EPS Next Y25.52%
EPS Next 2Y44.33%
EPS Next 3Y57.36%
EPS Next 5Y13.94%
Revenue Next Year15.96%
Revenue Next 2Y15.97%
Revenue Next 3Y14.93%
Revenue Next 5Y12.13%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
RIGL Yearly Revenue VS EstimatesRIGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
RIGL Yearly EPS VS EstimatesRIGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 9.04, the valuation of RIGL can be described as very reasonable.
Based on the Price/Earnings ratio, RIGL is valued cheaper than 97.30% of the companies in the same industry.
When comparing the Price/Earnings ratio of RIGL to the average of the S&P500 Index (27.21), we can say RIGL is valued rather cheaply.
The Price/Forward Earnings ratio is 9.55, which indicates a very decent valuation of RIGL.
Based on the Price/Forward Earnings ratio, RIGL is valued cheaper than 96.76% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.70, RIGL is valued rather cheaply.
Industry RankSector Rank
PE 9.04
Fwd PE 9.55
RIGL Price Earnings VS Forward Price EarningsRIGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, RIGL is valued cheaper than 98.56% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, RIGL is valued cheaper than 97.30% of the companies in the same industry.
Industry RankSector Rank
P/FCF 9.46
EV/EBITDA 6.17
RIGL Per share dataRIGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of RIGL may justify a higher PE ratio.
A more expensive valuation may be justified as RIGL's earnings are expected to grow with 57.36% in the coming years.
PEG (NY)0.35
PEG (5Y)N/A
EPS Next 2Y44.33%
EPS Next 3Y57.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RIGL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RIGEL PHARMACEUTICALS INC

NASDAQ:RIGL (7/1/2025, 9:05:24 PM)

After market: 18.82 +0.11 (+0.59%)

18.71

-0.02 (-0.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2025-05-06/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners80.38%
Inst Owner Change-47.26%
Ins Owners2.59%
Ins Owner Change10.65%
Market Cap334.35M
Analysts76.67
Price Target34.42 (83.97%)
Short Float %12.05%
Short Ratio10.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1609.36%
Min EPS beat(2)67.95%
Max EPS beat(2)3150.77%
EPS beat(4)4
Avg EPS beat(4)1093.78%
Min EPS beat(4)67.95%
Max EPS beat(4)3150.77%
EPS beat(8)7
Avg EPS beat(8)564.17%
EPS beat(12)11
Avg EPS beat(12)391.46%
EPS beat(16)13
Avg EPS beat(16)293.55%
Revenue beat(2)2
Avg Revenue beat(2)14.16%
Min Revenue beat(2)9.15%
Max Revenue beat(2)19.17%
Revenue beat(4)4
Avg Revenue beat(4)16.43%
Min Revenue beat(4)8.08%
Max Revenue beat(4)29.32%
Revenue beat(8)7
Avg Revenue beat(8)8.14%
Revenue beat(12)10
Avg Revenue beat(12)14.32%
Revenue beat(16)11
Avg Revenue beat(16)10.8%
PT rev (1m)0.22%
PT rev (3m)0.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.39%
EPS NY rev (1m)2.98%
EPS NY rev (3m)11.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.38%
Revenue NY rev (1m)-2%
Revenue NY rev (3m)0.2%
Valuation
Industry RankSector Rank
PE 9.04
Fwd PE 9.55
P/S 1.65
P/FCF 9.46
P/OCF 9.39
P/B 18.01
P/tB N/A
EV/EBITDA 6.17
EPS(TTM)2.07
EY11.06%
EPS(NY)1.96
Fwd EY10.47%
FCF(TTM)1.98
FCFY10.57%
OCF(TTM)1.99
OCFY10.64%
SpS11.36
BVpS1.04
TBVpS-0.44
PEG (NY)0.35
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 21.13%
ROE 200.24%
ROCE 40.18%
ROIC 31.74%
ROICexc 107.63%
ROICexgc 605.47%
OM 21.63%
PM (TTM) 18.31%
GM 89.64%
FCFM 17.4%
ROA(3y)-18.12%
ROA(5y)-18.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.38%
GM growth 5Y-1.87%
F-Score6
Asset Turnover1.15
Health
Industry RankSector Rank
Debt/Equity 2.42
Debt/FCF 1.69
Debt/EBITDA 0.97
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage 6.27
Cash Conversion 76.77%
Profit Quality 95.04%
Current Ratio 2.2
Quick Ratio 2.13
Altman-Z -7.17
F-Score6
WACC8.99%
ROIC/WACC3.53
Cap/Depr(3y)424.8%
Cap/Depr(5y)301.24%
Cap/Sales(3y)4.48%
Cap/Sales(5y)3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)272.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%226%
EPS Next Y25.52%
EPS Next 2Y44.33%
EPS Next 3Y57.36%
EPS Next 5Y13.94%
Revenue 1Y (TTM)68.74%
Revenue growth 3Y6.31%
Revenue growth 5Y24.77%
Sales Q2Q%80.58%
Revenue Next Year15.96%
Revenue Next 2Y15.97%
Revenue Next 3Y14.93%
Revenue Next 5Y12.13%
EBIT growth 1Y398.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year42.99%
EBIT Next 3Y76.86%
EBIT Next 5YN/A
FCF growth 1Y152.41%
FCF growth 3Y80.89%
FCF growth 5YN/A
OCF growth 1Y168.2%
OCF growth 3Y74.92%
OCF growth 5YN/A